Martin Dietrich is an Oncology physician affiliated with Cancer Care Centers of Brevard. OpenAlex indexes 82 publications with 3,043 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1048 Harvin Way
Rockledge, FL 329553229
Telephone
321-636-2111Provider last certified this registry record 3 Jan 2024.
Industry payments
110 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year2025126 payments$133,464openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202585 payments$115,316openpaymentsdata.cms.gov ↗
- Pharmacosmos Therapeutics Inc.Program year202572 payments$103,041openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
50.8%Substance P/Neurokinin-1 Receptor Antagonist40.8%Aprepitant100%Part B, office-administered≥11 patientsSerotonin-3 Receptor Antagonist9.7%Palonosetron hcl81%Ondansetron hydrochloride13%Ondansetron Hcl6%Part D + Part B≥61 patients+ 2 more classes in this area
Musculoskeletal
18.3%RANK Ligand Inhibitor18.3%Denosumab100%Part B, office-administered≥11 patientsBlood & clotting
10.5%Iron, parenteral preparations10.2%Ferric derisomaltose100%Part B, office-administered≥12 patientsFactor Xa inhibitor0.4%Eliquis71%Xarelto29%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”